pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
363
stories
13d
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
14d
Deep Dive: How AI is now essential in biopharma
biospace
14d
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
14d
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
14d
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
17d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
17d
STAT+: Up and down the ladder: The latest comings and goings
stat
17d
STAT+: Pharmalittle: We’re reading about licensing deals with China, making drugs in space, and more
stat
18d
A Parkinson's biotech debut, fundraising campaign and licensing deal
endpoints
18d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
18d
DPHARM: How to address the clinical trial enrollment crisis?
fiercebiotech
18d
Bavarian Nordic names Tarja Stenvall as new CEO
endpoints
18d
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
fiercebiotech
18d
STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
stat
19d
STAT+: Pharmalittle: We’re reading about faster FDA approvals, access to experimental drugs in Montana, and more
stat
20d
5 biotechs braving the commercial waters with product launches
biospace
20d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
20d
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
biospace
20d
STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
stat
21d
Abbott agrees to settlement over closure of largest baby formula plant in the U.S.
stat
21d
AstraZeneca’s newly approved pill fails frontline breast cancer study
biopharma dive
21d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
21d
Pennsylvania officials report state’s third death involving measles
stat
21d
STAT+: GSK touts lung cancer data from two drugs
stat
21d
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
21d
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
21d
AstraZeneca’s next-gen SERD Etcamah disappoints in untreated advanced breast cancer
endpoints
21d
STAT+: What’s in a name? Novo looks to a rebrand
stat
22d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
← prev
page 2 of 13
next →
